A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations

Detalhes bibliográficos
Autor(a) principal: Codevilla, Cristiane Franco
Data de Publicação: 2013
Outros Autores: Castilhos, Tamara dos Santos, Bergold, Ana Maria
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/196762
Resumo: The introduction of oral phosphodiesterase type 5 inhibitor therapy in 1998 revolutionized the treatment of erectile dysfunction. Erectile dysfunction is the most common sexual problem in men. It often has a profound effect on intimate relationships and quality of life. The analysis of pharmaceuticals is an important part of the drug development process as well as for routine analysis and quality control of commercial formulations. Whereas the determination of sildenafil citrate, vardenafil and tadalafil are well documented by a variety of methods, there are few publications about the determination of udenafil, lodenafil carbonate, mirodenafil and avanafil. The paper presents a brief review of the action mechanism, adverse effects, pharmacokinetics and the most recent analytical methods that can determine drug concentration in biological matrices and pharmaceutical formulations of these four drugs.
id UFRGS-2_21ecf31fb833762620d54012b4bff833
oai_identifier_str oai:www.lume.ufrgs.br:10183/196762
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Codevilla, Cristiane FrancoCastilhos, Tamara dos SantosBergold, Ana Maria2019-07-10T02:35:07Z20131984-8250http://hdl.handle.net/10183/196762000904420The introduction of oral phosphodiesterase type 5 inhibitor therapy in 1998 revolutionized the treatment of erectile dysfunction. Erectile dysfunction is the most common sexual problem in men. It often has a profound effect on intimate relationships and quality of life. The analysis of pharmaceuticals is an important part of the drug development process as well as for routine analysis and quality control of commercial formulations. Whereas the determination of sildenafil citrate, vardenafil and tadalafil are well documented by a variety of methods, there are few publications about the determination of udenafil, lodenafil carbonate, mirodenafil and avanafil. The paper presents a brief review of the action mechanism, adverse effects, pharmacokinetics and the most recent analytical methods that can determine drug concentration in biological matrices and pharmaceutical formulations of these four drugs.application/pdfengBrazilian journal of pharmaceutical sciences. São Paulo. Vol. 49, n. 1 (jan./mar. 2013), p. 1-11Disfunção erétil : tratamentoInibidores de fosfodiesteraseControle de qualidade de medicamentosPhosphodiesterase type 5 inhibitors/determination/pharmaceutical preparationsPhosphodiesterase type 5 inhibitors/determination/biological samplesAnalytical methodsErectile dysfunctionA review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparationsinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/otherinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT000904420.pdf.txt000904420.pdf.txtExtracted Texttext/plain44615http://www.lume.ufrgs.br/bitstream/10183/196762/2/000904420.pdf.txtfd74be19e9fd2ec1abd65ce954a23524MD52ORIGINAL000904420.pdfTexto completo (inglês)application/pdf672483http://www.lume.ufrgs.br/bitstream/10183/196762/1/000904420.pdff91ee821e0e71191ca45e0c77abfd358MD5110183/1967622019-07-11 02:35:30.141059oai:www.lume.ufrgs.br:10183/196762Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2019-07-11T05:35:30Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations
title A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations
spellingShingle A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations
Codevilla, Cristiane Franco
Disfunção erétil : tratamento
Inibidores de fosfodiesterase
Controle de qualidade de medicamentos
Phosphodiesterase type 5 inhibitors/determination/pharmaceutical preparations
Phosphodiesterase type 5 inhibitors/determination/biological samples
Analytical methods
Erectile dysfunction
title_short A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations
title_full A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations
title_fullStr A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations
title_full_unstemmed A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations
title_sort A review of analytical methods for the determination of four new phosphodiesterase type 5 inhibitors in biological samples and pharmaceutical preparations
author Codevilla, Cristiane Franco
author_facet Codevilla, Cristiane Franco
Castilhos, Tamara dos Santos
Bergold, Ana Maria
author_role author
author2 Castilhos, Tamara dos Santos
Bergold, Ana Maria
author2_role author
author
dc.contributor.author.fl_str_mv Codevilla, Cristiane Franco
Castilhos, Tamara dos Santos
Bergold, Ana Maria
dc.subject.por.fl_str_mv Disfunção erétil : tratamento
Inibidores de fosfodiesterase
Controle de qualidade de medicamentos
topic Disfunção erétil : tratamento
Inibidores de fosfodiesterase
Controle de qualidade de medicamentos
Phosphodiesterase type 5 inhibitors/determination/pharmaceutical preparations
Phosphodiesterase type 5 inhibitors/determination/biological samples
Analytical methods
Erectile dysfunction
dc.subject.eng.fl_str_mv Phosphodiesterase type 5 inhibitors/determination/pharmaceutical preparations
Phosphodiesterase type 5 inhibitors/determination/biological samples
Analytical methods
Erectile dysfunction
description The introduction of oral phosphodiesterase type 5 inhibitor therapy in 1998 revolutionized the treatment of erectile dysfunction. Erectile dysfunction is the most common sexual problem in men. It often has a profound effect on intimate relationships and quality of life. The analysis of pharmaceuticals is an important part of the drug development process as well as for routine analysis and quality control of commercial formulations. Whereas the determination of sildenafil citrate, vardenafil and tadalafil are well documented by a variety of methods, there are few publications about the determination of udenafil, lodenafil carbonate, mirodenafil and avanafil. The paper presents a brief review of the action mechanism, adverse effects, pharmacokinetics and the most recent analytical methods that can determine drug concentration in biological matrices and pharmaceutical formulations of these four drugs.
publishDate 2013
dc.date.issued.fl_str_mv 2013
dc.date.accessioned.fl_str_mv 2019-07-10T02:35:07Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/other
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/196762
dc.identifier.issn.pt_BR.fl_str_mv 1984-8250
dc.identifier.nrb.pt_BR.fl_str_mv 000904420
identifier_str_mv 1984-8250
000904420
url http://hdl.handle.net/10183/196762
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Brazilian journal of pharmaceutical sciences. São Paulo. Vol. 49, n. 1 (jan./mar. 2013), p. 1-11
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/196762/2/000904420.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/196762/1/000904420.pdf
bitstream.checksum.fl_str_mv fd74be19e9fd2ec1abd65ce954a23524
f91ee821e0e71191ca45e0c77abfd358
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1801224970789978112

Registros relacionados